SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants FDA findings from research published in bioRxiv using in vitro ...
FDA findings from research published in bioRxiv using in vitro pseudovirus models confirm SAB-185 broadly neutralizes variants of concern Non-Solicitation This press release is not a proxy statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results